Astellas and Vir Biotechnology Announce $1.71 Billion Deal to Develop Prostate Cancer Drug
Astellas Pharma and Vir Biotechnology have entered into a global collaboration to develop and commercialize VIR-5500, an experimental treatment for prostate cancer. As part of the agreement, both companies will share development expenses and revenues.
Under the terms, Astellas will lead the commercialization of VIR-5500 in the U.S., while Vir has the option to co-promote the drug. Outside the U.S., Astellas will have exclusive commercialization rights.
Vir Biotechnology will receive $335 million in upfront and near-term milestone payments from Astellas. Additionally, Vir could earn up to $1.37 billion in future development, regulatory, and sales milestones. Vir will also receive a share of U.S. profits or losses and tiered royalties from sales outside the U.S.
Following this announcement, shares of Vir Biotechnology rose sharply, with investors responding positively to both the partnership and the company's recent financial performance.
VIR-5500 is an experimental drug being developed to treat prostate cancer.
Astellas will handle commercialization in the U.S. and globally outside the U.S., while both companies will jointly develop the drug and share expenses and revenues.
The stock rose after the partnership news with Astellas and strong recent financial results.
Vir is set to receive $335 million upfront and could earn up to $1.37 billion more, plus a share of profits and royalties.
Reuters
Investors Business Daily
Forbes
Seeking Alpha
Business Wire